Advisory Agreements in the Biotechnology Industry
70 Contracts & Agreements
- Alliqua BioMedical, Inc. (1 contract)
- AmpliPhi Biosciences Corp (1)
- Aptevo Therapeutics Inc. (1)
- AVEO PHARMACEUTICALS INC (3)
- BioLife4D Corp (13)
- BIOXYTRAN, INC (6)
- Caribou Biosciences, Inc. (7)
- CRISPR Therapeutics AG (1)
- DelMar Pharmaceuticals, Inc. (1)
- Dynamics Special Purpose Corp. (1)
- Entrada Therapeutics, Inc. (1)
- Erasca, Inc. (1)
- FS Development Corp. (1)
- G1 Therapeutics, Inc. (2)
- Greater Cannabis Company, Inc. (1)
- GT Biopharma, Inc. (1)
- GX Acquisition Corp. (1)
- Immuneering Corp (1)
- International Stem Cell CORP (1)
- LIXTE BIOTECHNOLOGY HOLDINGS, INC. (1)
- Molecular Templates, Inc. (2)
- Moleculin Biotech, Inc. (1)
- Orgenesis Inc. (1)
- PepGen Inc. (1)
- PharmaCyte Biotech, Inc. (1)
- Q BioMed Inc. (3)
- Rezolute, Inc. (1)
- RITTER PHARMACEUTICALS INC (1)
- SELLAS Life Sciences Group, Inc. (5)
- Seres Therapeutics, Inc. (1)
- Solid Biosciences Inc. (1)
- Stellar Biotechnologies, Inc. (2)
- Stoke Therapeutics, Inc. (3)
- Synthetic Biologics, Inc. (1)
- Financial Advisory Agreement, dated as of November 9, 2023, between A.G.P./Alliance Global Partners and the Company (Aptevo Therapeutics Inc., Filed With SEC on November 9, 2023)
- Scientific Advisory Board Agreement between Senti Biosciences, Inc. and James Collins (Dynamics Special Purpose Corp., Filed With SEC on March 22, 2023)
- Advisory Agreement, as of August 16, 2022, by and between Celularity Inc. and Robin L. Smith (GX Acquisition Corp., Filed With SEC on November 10, 2022)
- Scientific Advisory Board Agreement by and between Adrian Krainer, Ph.D. and the Registrant, dated June 1, 2022 (Stoke Therapeutics, Inc., Filed With SEC on August 8, 2022)
- Scientific Advisory Board Member Agreement, dated as of July 19, 2022, between the Registrant and Caroline Godfrey (PepGen Inc., Filed With SEC on July 22, 2022)
- Amendment to Advisory Board Agreement between BioLife4D Corporation and Ibrahim T. Ozbolat, dated January 14, 2022 (BioLife4D Corp, Filed With SEC on July 21, 2022)
- Advisory Board Agreement between BioLife4D Corporation and Stephen M. Simes, dated January 21, 2019 (BioLife4D Corp, Filed With SEC on June 3, 2022)
- Advisory Board Agreement between BioLife4D Corporation and Raimond Winslow, dated August 28, 2017 (BioLife4D Corp, Filed With SEC on June 3, 2022)
- Amendment to Advisory Board Agreement between BioLife4D Corporation and Jeffrey Morgan, dated February 1, 2022 (BioLife4D Corp, Filed With SEC on June 3, 2022)
- Advisory Board Agreement between BioLife4D Corporation and Jeffrey Morgan, dated August 23, 2017 (BioLife4D Corp, Filed With SEC on June 3, 2022)
- Amendment to Advisory Board Agreement between BioLife4D Corporation and Shayn Peirce-Cottler, dated February 1, 2022 (BioLife4D Corp, Filed With SEC on June 3, 2022)
- Advisory Board Agreement between BioLife4D Corporation and Shayn Peirce-Cottler, dated July 11, 2017 (BioLife4D Corp, Filed With SEC on June 3, 2022)
- Amendment to Advisory Board Agreement between BioLife4D Corporation and Janet Zoldan, dated February 1, 2022 (BioLife4D Corp, Filed With SEC on June 3, 2022)
- Advisory Board Agreement between BioLife4D Corporation and Janet Zoldan, dated June 8, 2017 (BioLife4D Corp, Filed With SEC on June 3, 2022)
- Amendment to Advisory Board Agreement between BioLife4D Corporation and Ibrahim T. Ozbolat, dated January 14, 2022 (BioLife4D Corp, Filed With SEC on June 3, 2022)
- Advisory Board Agreement between BioLife4D Corporation and Ibrahim T. Ozbolat, dated May 31, 2017 (BioLife4D Corp, Filed With SEC on June 3, 2022)
- Amendment to Advisory Board Agreement between BioLife4D Corporation and Sean Palecek, dated January 17, 2022 (BioLife4D Corp, Filed With SEC on June 3, 2022)
- Advisory Board Agreement between BioLife4D Corporation and Sean Palecek, dated May 30, 2017 (BioLife4D Corp, Filed With SEC on June 3, 2022)
- Advisory Agreement, dated as of April 15, 2022, by and between Gemini Therapeutics, Inc. and Dr. Samuel Barone (FS Development Corp., Filed With SEC on May 6, 2022)
- Advisory Agreement, dated March 28, 2022, between the Company and Mr. Martin (AmpliPhi Biosciences Corp, Filed With SEC on March 28, 2022)
- Scientific Advisory Board Agreement by and between the Registrant and Adrian Krainer, Ph.D., dated June 1, 2021 (Stoke Therapeutics, Inc., Filed With SEC on March 10, 2022)
- Amended and Restated Strategic Advisory Agreement, by and between the Registrant and Peter S. Kim, to be in effect as of the closing of this offering (Entrada Therapeutics, Inc., Filed With SEC on October 25, 2021)
- Advisory Agreement, dated September 17, 2019, by and between PEF LLC and the Registrant (Immuneering Corp, Filed With SEC on July 9, 2021)
- Scientific Advisory Board Agreement, dated January 1, 2017, by and between the Registrant and Jennifer A. Doudna (Caribou Biosciences, Inc., Filed With SEC on July 1, 2021)
- Amendment No. 5 to Scientific Advisory Board Agreement, dated as of January 1, 2020, by and between the Registrant and Jennifer A. Doudna (Caribou Biosciences, Inc., Filed With SEC on July 1, 2021)
- Amendment No. 4 to Scientific Advisory Board Agreement, dated as of March 31, 2018, by and between the Registrant and Jennifer A. Doudna (Caribou Biosciences, Inc., Filed With SEC on July 1, 2021)
- Amendment No. 3 to Scientific Advisory Board Agreement, dated as of January 1, 2017, by and between the Registrant and Jennifer A. Doudna (Caribou Biosciences, Inc., Filed With SEC on July 1, 2021)
- Amendment No. 2 to Scientific Advisory Board Agreement, dated as of May 31, 2016, by and between the Registrant and Jennifer A. Doudna (Caribou Biosciences, Inc., Filed With SEC on July 1, 2021)
- Amendment No. 1 to Scientific Advisory Board Agreement, dated as of April 12, 2014, by and between the Registrant and Jennifer A. Doudna (Caribou Biosciences, Inc., Filed With SEC on July 1, 2021)
- Scientific Advisory Board Agreement, dated as of June 18, 2012, by and between the Registrant and Jennifer A. Doudna (Caribou Biosciences, Inc., Filed With SEC on July 1, 2021)
- Scientific Advisory Board Agreement, dated August 15, 2020, by and between Michael D. Varney, Ph.D. and the Registrant (Erasca, Inc., Filed With SEC on June 25, 2021)
- Letter agreement amending M&A Advisory Agreement between the Company and A.G.P./Alliance Global Partners dated May 20, 2020 (RITTER PHARMACEUTICALS INC, Filed With SEC on August 14, 2020)
- Scientific Advisory Board Agreement, June 2020 (Stoke Therapeutics, Inc., Filed With SEC on August 10, 2020)
- Scientific Advisory Board Agreement, dated (Moleculin Biotech, Inc., Filed With SEC on March 19, 2020)
- Advisory Agreement, dated December 12, 2019, by and between the Registrant and Roger Pomerantz (Seres Therapeutics, Inc., Filed With SEC on March 2, 2020)
- Financial Advisory Agreement, dated November 5, 2019, between Edesa Biotech, Inc. and Brookline Capital Markets, a division of Arcadia Securities, LLC (Stellar Biotechnologies, Inc., Filed With SEC on January 6, 2020)
- Amendment to Financial Advisory Agreement, dated December 20, 2019, between Edesa Biotech, Inc. and Brookline Capital Markets, a division of Arcadia Securities, LLC (Stellar Biotechnologies, Inc., Filed With SEC on January 6, 2020)
- Form of Advisory Board Agreement between Bioxytran, Inc. and Patrick Huddie dated September 13, 2019 (BIOXYTRAN, INC, Filed With SEC on September 13, 2019)
- Form of Advisory Board Agreement between Bioxytran, Inc. and Jonathan Jensen Dated September 13, 2019 (BIOXYTRAN, INC, Filed With SEC on September 13, 2019)
- Form of Advisory Board Agreement between Bioxytran, Inc. and Cynthia Tsai effective July 16, 2019 (BIOXYTRAN, INC, Filed With SEC on August 1, 2019)
